Amylyx Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Material agreementSep 8 →Insiders1 insider bought $152,183 in 2 open-market buys. 5 insiders sold $5.8M, 0 of 18 sales on a 10b5-1 plan.→HoldersFMR 15.0%BlackRock 7.9%Perceptive 7.5%→Financing →PeersClosest companies: MBX, VRDN, SEPN→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$152.1Mlast 12 months
- Operating cash flow
- −$120.4Mlast 12 months
- Cash and equivalents
- $49.3Mat the last balance sheet
- Shares outstanding
- 111.4M shareson issue